Focus: Kezar Life Sciences is a South San Francisco-based biotechnology company focused on developing therapies for autoimmune disorders, particularly in immunology. The company operates as a clinical-stage biotech with a focused pipeline in rare and serious autoimmune indications.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Kezar Life Sciences to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Kezar Life Sciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Kezar Life Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Kezar Life Sciences (NASDAQ: KZR) details Aurinia tender offer, pay and ownership - Stock Titan
Kezar Life Sciences (NASDAQ: KZR) details Aurinia tender offer, pay and ownership Stock Titan
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Kezar Life Sciences shares surge after Aurinia announces acquisition MSN
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - MSN
Aurinia Pharmaceuticals acquiring Kezar Life Sciences MSN
Aurinia to buy Kezar (KZR) for $6.955/Share plus CVR (7.39M shares) - Stock Titan
Aurinia to buy Kezar (KZR) for $6.955/Share plus CVR (7.39M shares) Stock Titan
Aurinia Pharmaceuticals Acquisition Of Kezar Reshapes Autoimmune Growth And Risks - simplywall.st
Aurinia Pharmaceuticals Acquisition Of Kezar Reshapes Autoimmune Growth And Risks simplywall.st
How a four-month FDA delay forced a small biotech company to close its doors - statnews.com
How a four-month FDA delay forced a small biotech company to close its doors statnews.com
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications